[1] |
LIANG Jie.
172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
|
[2] |
QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao.
Research Progress in Integration Sites for Cellular and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
|
[3] |
WANG Chunting, CHEN Yafei.
Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
|
[4] |
ZHU Huijuan, REN Jingtian.
Safety Risks of Human Rabies Immunoglobulin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
|
[5] |
LI Ying, HUANG Lishuang, ZHANG Jingjing, ZHU Yuanchao, SHEN Ji, YANG Jun.
Pharmaceutical Care to a Geriatric Syndrome Patient with Heart Failure Combined with Uremia
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 805-808.
|
[6] |
LI Can, LIU Lehuan, CHEN Xia, QU Jianbo.
Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
|
[7] |
WANG Fengxin, LI Lei, HUANG Xurui, ZHAO Yun, LING Ruby, YANG Yang, LIANG Changhao, ZENG Yuntao, ZHENG Yingjun, TANG Yuanchen, LIU Jiatao, WANG Chengxiang, WEN Tiancai, LI Ping.
Efficacy and Safety of Danshen Decoction in Treatment of Coronary Heart Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 575-579.
|
[8] |
YAN Caiying, QIN Linying, XU Yaoqing, WANG Xinge, CHAI Nannan, CHEN Long.
Research Progress in Uric Acid-Lowering Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 592-595.
|
[9] |
CHEN Huan, LIANG Jun, ZHAO Wei, XIA Qingrong.
Clinical Features and Risk Factors of Liver Injury Induced by Atypical Antipsychotic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 410-414.
|
[10] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[11] |
WANG Shuan, HUANG Can, QI Lamei.
Establishment and Evaluation of Apatinib-Induced Hypertension Prediction Model Based on Real-World Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 429-435.
|
[12] |
LONG Minjuan, ZHAO Xu, GUO Longxin, CAI Yuhan, LIN Li, ZHU Shengkai, LIU Wenlong, SONG Haibo, XIAO Xiaohe.
Big Data Analysis of Liver Adverse Reactions Monitoring of Chinese and Western Medicines Based on Age Correction and Risk Warning for Dermatologic Drugs
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 271-275.
|
[13] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[14] |
LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan.
Methods for Assessment of MAH Compliance with GVP
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
|
[15] |
LIAO Mengfan, ZHONG Liling, XU Yan, LIU Ying, ZHANG Yexiang, CHEN Qingsong, LIU Xudong.
Adverse Reactions to Antihypertensive and Hypoglycaemic Drugs Based on Spontaneous Presentation Systems
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 286-291.
|